They're just one-tenth the size of conventional antibodies, and have not been found in any other mammals, say scientists.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...

Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine ...

"AHA 2025: SHR-1918’s impact on hyperlipidaemia through angiopoietin-like 3 inhibition" was originally created and published ...

Prior exposure to coronaviruses that cause ordinary colds can boost the immune system's ability to attack a vulnerable site ...

A newly developed mouse model enables real-time visualization of RNA Polymerase II (RNAP2) during DNA transcription, as ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...